| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Polysaccharides | 34 | 2022 | 176 | 6.480 |
Why?
|
| Carcinoma, Hepatocellular | 21 | 2022 | 163 | 6.250 |
Why?
|
| Liver Neoplasms | 19 | 2022 | 334 | 5.480 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 28 | 2022 | 306 | 3.830 |
Why?
|
| Glycoproteins | 15 | 2022 | 238 | 3.310 |
Why?
|
| Biomarkers, Tumor | 16 | 2022 | 508 | 3.220 |
Why?
|
| Glycosylation | 25 | 2022 | 185 | 2.240 |
Why?
|
| Early Detection of Cancer | 5 | 2020 | 454 | 1.640 |
Why?
|
| Glycomics | 7 | 2022 | 29 | 1.510 |
Why?
|
| Liver Cirrhosis | 6 | 2022 | 301 | 1.480 |
Why?
|
| Fucose | 7 | 2019 | 25 | 1.460 |
Why?
|
| Kininogens | 3 | 2018 | 88 | 1.270 |
Why?
|
| Immunoglobulin G | 6 | 2022 | 481 | 1.230 |
Why?
|
| Proteomics | 6 | 2022 | 246 | 1.110 |
Why?
|
| Biomarkers | 7 | 2022 | 1593 | 1.040 |
Why?
|
| Hepatitis B virus | 7 | 2011 | 23 | 0.900 |
Why?
|
| Viral Envelope Proteins | 5 | 2011 | 43 | 0.830 |
Why?
|
| Neuraminidase | 1 | 2022 | 36 | 0.820 |
Why?
|
| Algorithms | 2 | 2018 | 1196 | 0.800 |
Why?
|
| Paraffin Embedding | 8 | 2021 | 47 | 0.770 |
Why?
|
| Protein Processing, Post-Translational | 6 | 2021 | 284 | 0.760 |
Why?
|
| Acetylglucosamine | 1 | 2020 | 46 | 0.700 |
Why?
|
| alpha-2-HS-Glycoprotein | 2 | 2017 | 11 | 0.680 |
Why?
|
| Lectins | 6 | 2020 | 81 | 0.680 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 65 | 0.660 |
Why?
|
| Optical Imaging | 1 | 2019 | 46 | 0.650 |
Why?
|
| Antibodies, Heterophile | 1 | 2018 | 11 | 0.640 |
Why?
|
| Humans | 57 | 2022 | 68618 | 0.640 |
Why?
|
| Extracellular Matrix | 5 | 2021 | 493 | 0.610 |
Why?
|
| Tissue Fixation | 6 | 2021 | 58 | 0.600 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 756 | 0.600 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 20 | 0.590 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 39 | 0.580 |
Why?
|
| Antiviral Agents | 4 | 2013 | 211 | 0.580 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 307 | 0.550 |
Why?
|
| Enzyme Inhibitors | 3 | 2010 | 659 | 0.480 |
Why?
|
| Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 4 | 2022 | 19 | 0.480 |
Why?
|
| Liver | 3 | 2022 | 1118 | 0.470 |
Why?
|
| Formaldehyde | 6 | 2021 | 48 | 0.470 |
Why?
|
| Glycoside Hydrolases | 3 | 2022 | 25 | 0.430 |
Why?
|
| Antigen Presentation | 2 | 2011 | 76 | 0.400 |
Why?
|
| Middle Aged | 14 | 2022 | 21147 | 0.390 |
Why?
|
| Histocytochemistry | 3 | 2021 | 149 | 0.390 |
Why?
|
| Mass Spectrometry | 5 | 2022 | 284 | 0.390 |
Why?
|
| Peptides | 5 | 2021 | 455 | 0.380 |
Why?
|
| Ubiquitin | 1 | 2011 | 74 | 0.370 |
Why?
|
| Aortic Valve | 3 | 2021 | 249 | 0.370 |
Why?
|
| Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase | 5 | 2022 | 17 | 0.370 |
Why?
|
| 1-Deoxynojirimycin | 2 | 2010 | 2 | 0.360 |
Why?
|
| Male | 17 | 2022 | 37321 | 0.350 |
Why?
|
| Collagen | 3 | 2021 | 636 | 0.350 |
Why?
|
| Sensitivity and Specificity | 4 | 2018 | 1753 | 0.350 |
Why?
|
| Sialic Acids | 2 | 2022 | 27 | 0.350 |
Why?
|
| Glucosidases | 2 | 2010 | 4 | 0.340 |
Why?
|
| Female | 19 | 2022 | 38074 | 0.340 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 332 | 0.340 |
Why?
|
| Amino Sugars | 2 | 2019 | 12 | 0.330 |
Why?
|
| Aortic Valve Stenosis | 2 | 2021 | 177 | 0.330 |
Why?
|
| Hepatitis C | 1 | 2007 | 114 | 0.270 |
Why?
|
| Serum | 1 | 2006 | 24 | 0.270 |
Why?
|
| Molecular Imaging | 3 | 2021 | 45 | 0.250 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 71 | 0.250 |
Why?
|
| Membrane Proteins | 4 | 2012 | 617 | 0.250 |
Why?
|
| Tissue Array Analysis | 3 | 2020 | 53 | 0.230 |
Why?
|
| Kidney | 3 | 2020 | 945 | 0.230 |
Why?
|
| Research Design | 3 | 2022 | 729 | 0.220 |
Why?
|
| Adult | 10 | 2020 | 21403 | 0.210 |
Why?
|
| Borrelia burgdorferi | 1 | 2022 | 11 | 0.210 |
Why?
|
| Lyme Disease | 1 | 2022 | 17 | 0.210 |
Why?
|
| Aged | 6 | 2018 | 14862 | 0.200 |
Why?
|
| Primary Graft Dysfunction | 1 | 2021 | 12 | 0.200 |
Why?
|
| Phosphofructokinase-1, Type C | 1 | 2021 | 7 | 0.200 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 22 | 0.190 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 48 | 0.190 |
Why?
|
| Breast Neoplasms | 2 | 2022 | 1536 | 0.190 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 2020 | 14 | 0.190 |
Why?
|
| Fixatives | 1 | 2021 | 24 | 0.190 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2022 | 87 | 0.190 |
Why?
|
| Lung Transplantation | 1 | 2021 | 88 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 46 | 0.180 |
Why?
|
| Workflow | 4 | 2021 | 100 | 0.180 |
Why?
|
| Animals | 16 | 2022 | 20881 | 0.170 |
Why?
|
| T-Lymphocytes, Cytotoxic | 2 | 2011 | 79 | 0.170 |
Why?
|
| Hepatitis B | 2 | 2013 | 42 | 0.170 |
Why?
|
| Carbohydrate Epimerases | 1 | 2019 | 1 | 0.170 |
Why?
|
| Guanosine Diphosphate Fucose | 1 | 2019 | 2 | 0.170 |
Why?
|
| Ketone Oxidoreductases | 1 | 2019 | 2 | 0.170 |
Why?
|
| Hydro-Lyases | 1 | 2019 | 4 | 0.170 |
Why?
|
| Biocompatible Materials | 1 | 2021 | 247 | 0.170 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 201 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 27 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2011 | 69 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 110 | 0.160 |
Why?
|
| Antibodies | 1 | 2019 | 241 | 0.160 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2021 | 207 | 0.160 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2019 | 41 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2020 | 206 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2018 | 132 | 0.150 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 129 | 0.150 |
Why?
|
| ROC Curve | 2 | 2009 | 392 | 0.150 |
Why?
|
| Breast | 1 | 2018 | 137 | 0.150 |
Why?
|
| DNA Methylation | 1 | 2019 | 193 | 0.150 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 172 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 149 | 0.150 |
Why?
|
| Case-Control Studies | 2 | 2019 | 1553 | 0.150 |
Why?
|
| alpha-Fetoproteins | 1 | 2017 | 22 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 536 | 0.140 |
Why?
|
| Hepacivirus | 3 | 2007 | 90 | 0.140 |
Why?
|
| Fucosyltransferases | 2 | 2020 | 6 | 0.140 |
Why?
|
| Linear Models | 1 | 2018 | 521 | 0.140 |
Why?
|
| Molecular Sequence Data | 5 | 2014 | 1447 | 0.140 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 1851 | 0.140 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 807 | 0.130 |
Why?
|
| Heart Defects, Congenital | 1 | 2021 | 596 | 0.130 |
Why?
|
| Mutation | 2 | 2019 | 1213 | 0.130 |
Why?
|
| Tumor Cells, Cultured | 4 | 2021 | 852 | 0.130 |
Why?
|
| Recurrence | 1 | 2018 | 948 | 0.130 |
Why?
|
| Prostatic Neoplasms | 2 | 2014 | 778 | 0.130 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 2006 | 50 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1140 | 0.120 |
Why?
|
| Chronic Disease | 1 | 2018 | 1330 | 0.110 |
Why?
|
| Crohn Disease | 1 | 2013 | 38 | 0.110 |
Why?
|
| Colitis, Ulcerative | 1 | 2013 | 53 | 0.110 |
Why?
|
| Young Adult | 3 | 2020 | 5717 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2015 | 682 | 0.110 |
Why?
|
| Mice | 7 | 2022 | 8474 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 73 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4848 | 0.100 |
Why?
|
| Carbohydrate Conformation | 3 | 2021 | 25 | 0.100 |
Why?
|
| Oncostatin M | 1 | 2012 | 5 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 475 | 0.100 |
Why?
|
| Cytosol | 1 | 2011 | 123 | 0.100 |
Why?
|
| Ubiquitination | 1 | 2011 | 85 | 0.100 |
Why?
|
| Proteolysis | 1 | 2011 | 97 | 0.090 |
Why?
|
| Indolizines | 1 | 2010 | 3 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 14 | 0.090 |
Why?
|
| Isomerism | 2 | 2021 | 63 | 0.090 |
Why?
|
| Lysosomes | 1 | 2011 | 136 | 0.090 |
Why?
|
| Protein Isoforms | 1 | 2011 | 246 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2011 | 326 | 0.090 |
Why?
|
| Elastin | 2 | 2021 | 116 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2012 | 330 | 0.090 |
Why?
|
| Marmota | 2 | 2010 | 4 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2021 | 282 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2009 | 954 | 0.080 |
Why?
|
| Hemopexin | 1 | 2009 | 2 | 0.080 |
Why?
|
| Immunoassay | 1 | 2009 | 64 | 0.080 |
Why?
|
| alpha-Glucosidases | 1 | 2008 | 2 | 0.080 |
Why?
|
| Semen | 1 | 2009 | 29 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2009 | 56 | 0.080 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 507 | 0.080 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2009 | 61 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2008 | 24 | 0.080 |
Why?
|
| Blood Proteins | 1 | 2009 | 94 | 0.080 |
Why?
|
| Area Under Curve | 1 | 2009 | 238 | 0.080 |
Why?
|
| Oligosaccharides, Branched-Chain | 1 | 2008 | 1 | 0.080 |
Why?
|
| DNA, Viral | 2 | 2006 | 114 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2009 | 138 | 0.080 |
Why?
|
| Trisaccharides | 1 | 2007 | 1 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1174 | 0.080 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 306 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 1293 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2009 | 800 | 0.070 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2006 | 7 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2018 | 7277 | 0.070 |
Why?
|
| Lamivudine | 1 | 2006 | 24 | 0.070 |
Why?
|
| Hepatitis B, Chronic | 1 | 2006 | 19 | 0.070 |
Why?
|
| Carbohydrate Sequence | 3 | 2014 | 45 | 0.070 |
Why?
|
| Cell Survival | 2 | 2006 | 901 | 0.070 |
Why?
|
| Immunoglobulins | 1 | 2006 | 97 | 0.060 |
Why?
|
| Oligopeptides | 1 | 2006 | 152 | 0.060 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 226 | 0.060 |
Why?
|
| Oligosaccharides | 1 | 2005 | 26 | 0.060 |
Why?
|
| HIV Infections | 1 | 2013 | 791 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2006 | 420 | 0.060 |
Why?
|
| United States | 1 | 2017 | 7367 | 0.060 |
Why?
|
| Galactosylceramides | 1 | 2004 | 12 | 0.060 |
Why?
|
| Glycolipids | 1 | 2004 | 20 | 0.060 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 2550 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2012 | 1664 | 0.060 |
Why?
|
| Apolipoproteins C | 1 | 2003 | 15 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2004 | 156 | 0.060 |
Why?
|
| Apolipoprotein A-I | 1 | 2003 | 29 | 0.060 |
Why?
|
| Prognosis | 2 | 2021 | 2093 | 0.050 |
Why?
|
| Brain | 1 | 2013 | 2176 | 0.050 |
Why?
|
| Diet, Western | 1 | 2022 | 17 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1745 | 0.050 |
Why?
|
| Karyopherins | 1 | 2021 | 11 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2021 | 55 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 28 | 0.050 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2021 | 57 | 0.050 |
Why?
|
| Hydroxylation | 1 | 2021 | 41 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2021 | 138 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 91 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 90 | 0.050 |
Why?
|
| Microtomy | 1 | 2020 | 11 | 0.050 |
Why?
|
| Mice, SCID | 1 | 2021 | 238 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 68 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2021 | 234 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 2013 | 9 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 369 | 0.040 |
Why?
|
| Child | 2 | 2021 | 6405 | 0.040 |
Why?
|
| Mammography | 1 | 2022 | 310 | 0.040 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2020 | 39 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2020 | 144 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 225 | 0.040 |
Why?
|
| Research | 1 | 2021 | 214 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2021 | 546 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2021 | 483 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2022 | 867 | 0.040 |
Why?
|
| Autoantibodies | 1 | 2021 | 434 | 0.040 |
Why?
|
| Fibrosis | 1 | 2021 | 371 | 0.040 |
Why?
|
| Breast Diseases | 1 | 2018 | 40 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 381 | 0.040 |
Why?
|
| Microscopy | 1 | 2018 | 64 | 0.040 |
Why?
|
| Transfection | 2 | 2011 | 782 | 0.040 |
Why?
|
| Epitopes | 2 | 2010 | 146 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2019 | 532 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2019 | 258 | 0.040 |
Why?
|
| Trypsin | 1 | 2018 | 64 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 714 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 786 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 689 | 0.040 |
Why?
|
| Heart | 1 | 2021 | 850 | 0.030 |
Why?
|
| Liposarcoma, Myxoid | 1 | 2016 | 5 | 0.030 |
Why?
|
| Leiomyosarcoma | 1 | 2016 | 17 | 0.030 |
Why?
|
| Antigens | 1 | 2016 | 90 | 0.030 |
Why?
|
| Phenotype | 2 | 2013 | 947 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 498 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1030 | 0.030 |
Why?
|
| Viral Proteins | 2 | 2008 | 150 | 0.030 |
Why?
|
| Myocardium | 1 | 2021 | 1204 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2673 | 0.030 |
Why?
|
| Molecular Probes | 1 | 2015 | 27 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2021 | 2455 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 1038 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 2791 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2077 | 0.030 |
Why?
|
| Paraffin | 1 | 2014 | 7 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2015 | 101 | 0.030 |
Why?
|
| Infant | 1 | 2021 | 2891 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2014 | 144 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2021 | 3187 | 0.030 |
Why?
|
| Coinfection | 1 | 2013 | 30 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2013 | 180 | 0.030 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 98 | 0.030 |
Why?
|
| Viral Load | 1 | 2013 | 127 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2012 | 68 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2011 | 42 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 561 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2011 | 165 | 0.020 |
Why?
|
| Hepatitis B Virus, Woodchuck | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cricetinae | 1 | 2011 | 262 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 737 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 312 | 0.020 |
Why?
|
| Protein Transport | 1 | 2011 | 280 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 124 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1015 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2009 | 36 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2008 | 14 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2008 | 34 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 931 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 770 | 0.020 |
Why?
|
| Adolescent | 1 | 2021 | 8912 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 2008 | 73 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 3259 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2013 | 2358 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2008 | 1083 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2006 | 25 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2013 | 3705 | 0.020 |
Why?
|
| Interferon-beta | 1 | 2004 | 17 | 0.010 |
Why?
|
| Kinetics | 1 | 2006 | 1047 | 0.010 |
Why?
|
| Porifera | 1 | 2004 | 58 | 0.010 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2003 | 38 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2003 | 93 | 0.010 |
Why?
|
| Cell Line | 1 | 2004 | 1752 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 5731 | 0.010 |
Why?
|
| Models, Biological | 1 | 2003 | 981 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 4655 | 0.010 |
Why?
|